Literature DB >> 15950365

Prevalence of high-risk human papillomavirus (HR-HPV) types 16 and 18 in healthy women with cytologically negative Pap smear.

Raksha Arora1, Arunaz Kumar, Bhupesh K Prusty, Uma Kailash, Swaraj Batra, Bhudev C Das.   

Abstract

OBJECTIVE: To study the prevalence of high-risk human papillomavirus (HR-HPV) types 16 and 18 in healthy women with negative Pap smears in identifying women with underlying cervical squamous intra-epithelial (SIL) lesions.
METHODS: A total of 3300 women who were attending the Gynecology OPD of Lok Nayak Hospital, one of the major government tertiary hospitals in New Delhi, were screened during a 1-year study period, and 2079 (63%) of them were found to have cytologically negative Pap smear with inflammation and the rest (37%) also had negative Pap report but without inflammation. Hundred and sixty of these sexually active women aged between 20 and 60 years were randomly selected, and were investigated by colposcopy and a guided biopsy was done wherever required. HPV types 16 and 18 DNA was detected in scraped cervical cells from all women using type-specific primers in polymerase chain reaction (PCR).
RESULTS: The high-risk HPV (type 16 and 18) prevalence by PCR was found to be 10% (16/160). Histopathological findings were obtained in 123 women, out of which 15 had LSIL and four had HSIL. High-risk HPV types 16/18 could be detected in nine out of these 19 (47.3%) squamous intra-epithelial lesions (p < 0.00008) which includes two out of the four women (50%) having HSIL, while only seven out of 104 (6.7%) of the subjects with normal (negative) Pap reports (p = 0.03) had infection of high-risk HPV.
CONCLUSION: The results indicate that about 10% of women who show a negative Pap smear, but have inflammation are positive for high-risk HPV types 16/18 and about 15% harbor squamous intra-epithelial lesions. It is suggested that high-risk HPV detection can be utilized as an adjunct to routine cytology screening programs to identify 'high risk' women who have concurrently negative Pap smears but may harbor oncogenic HPV infection and/or more likely to develop CIN lesions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15950365     DOI: 10.1016/j.ejogrb.2004.11.025

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  8 in total

1.  Prevalence of Human Papilloma Virus Infection in Young Primiparous Women During Postpartum Period: Study from a Tertiary Care Center in Northern India.

Authors:  Alpana Garg; Vanita Suri; Raje Nijhawan; Neelam Aggarwal; Ritu Aggarwal; Charu Guleria; Mili Thakur
Journal:  J Clin Diagn Res       Date:  2016-10-01

2.  Telomerase activity as an adjunct to high-risk human papillomavirus types 16 and 18 and cytology screening in cervical cancer.

Authors:  U Kailash; C C Soundararajan; R Lakshmy; R Arora; S Vivekanandhan; B C Das
Journal:  Br J Cancer       Date:  2006-10-24       Impact factor: 7.640

3.  Genotypic distribution of human papillomavirus (HPV) and cervical cytology findings in 5906 Thai women undergoing cervical cancer screening programs.

Authors:  Nuttavut Kantathavorn; Chulabhorn Mahidol; Narongrit Sritana; Thaniya Sricharunrat; Natacha Phoolcharoen; Chirayu Auewarakul; Narongchai Teerayathanakul; Chantanee Taepisitpong; Siriporn Saeloo; Gaidganok Sornsamdang; Wandee Udomchaiprasertkul; Waraphorn Krongthong; Arpaporn Arnamwong
Journal:  Infect Agent Cancer       Date:  2015-03-02       Impact factor: 2.965

Review 4.  Epidemiology of cervical cancer with special focus on India.

Authors:  Aswathy Sreedevi; Reshma Javed; Avani Dinesh
Journal:  Int J Womens Health       Date:  2015-04-16

5.  High-risk human papilloma virus and cervical abnormalities in HIV-infected women with normal cervical cytology.

Authors:  Jonah Musa; Chad Achenbach; Babafemi Taiwo; Baiba Berzins; Olugbenga Silas; Patrick H Daru; Oche Agbaji; Godwin Imade; Atiene S Sagay; John A Idoko; Phyllis J Kanki; Robert L Murphy
Journal:  Infect Agent Cancer       Date:  2014-11-03       Impact factor: 2.965

6.  Development and validation of a HPV-32 specific PCR assay.

Authors:  Nicholas R Herrel; Nadia L Johnson; Jennifer E Cameron; Janet Leigh; Michael E Hagensee
Journal:  Virol J       Date:  2009-06-27       Impact factor: 4.099

7.  Human papillomavirus (HPV) prevalence and types among Turkish women at a gynecology outpatient unit.

Authors:  Polat Dursun; Süheyla S Senger; Hande Arslan; Esra Kuşçu; Ali Ayhan
Journal:  BMC Infect Dis       Date:  2009-11-30       Impact factor: 3.090

8.  Human papillomavirus (HPV) infection and intraepithelial neoplasia and invasive cancer of the uterine cervix: a case-control study in Zaragoza, Spain.

Authors:  Milagros Bernal; Isabel Burillo; Jose I Mayordomo; Manuel Moros; Rafael Benito; Joaquina Gil
Journal:  Infect Agent Cancer       Date:  2008-05-29       Impact factor: 2.965

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.